What is the success rate of Breyanzi?
The success rate of Breyanzi (lisocabtagene maraleucel) varies depending on the condition being treated. Clinical trial data show that complete response rates range from 20% to 73% across different types of lymphoma and leukemia.
Below are clinical trial results for Breyanzi in various conditions, with some patients experiencing partial response to treatment.
Large B-cell lymphoma
Breyanzi was studied in over 250 adults with refractory or relapsed B-cell lymphoma in a multicenter clinical trial. The study showed:
- After treatment with Breyanzi, the complete remission rate was 54%.
- Criteria: 2014 Lugano classification
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
The complete response rate among patients who took Breyanzi for relapsed or refractory CLL or SLL in a clinical trial called TRANSCEND-CLL was 20%. A total of 65 patients were treated with Breyanzi in the study.
- Criteria: 2018 International Workshop CLL (iwCLL) criteria
Related questions
- Prednisone: What are 12 Things You Should Know?
- What are CHOP and R-CHOP chemotherapy regimens?
- What is the difference between Truxima and Rituxan?
Follicular lymphoma
In the TRANSCEND-FL clinical trial, adults with relapsed or refractory follicular lymphoma who took Breyanzi had a complete response rate of 73.4%. A total of 94 patients that were treated with Breyanzi were included in the final results. In order to be considered to have complete response, patients who did not have a negative bone marrow biopsy between their most recent disease progression and before starting lymphodepleting chemotherapy were required to have a negative bone marrow biopsy.
Mantle cell lymphoma
Out of 68 patients with relapsed or refractory mantle cell lymphoma who were treated with Breyanzi in the TRANSCEND-MCL trial, 67.6% saw a complete response.
- Criteria: 2014 Lugano classification
Individual responses to Breyanzi vary, and partial responses were also observed in these trials. Speak with your healthcare provider to understand how these results may apply to your specific situation.
References
Breyanzi [package insert]. Updated May 2024. Juno Therapeutics, Inc. Accessed August 6, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed
U.S. Food and Drug Administration. 2021. FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma. Accessed August 6, 2024 at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-or-refractory-large-b-cell-lymphoma
U.S. Food and Drug Administration. 2024. FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma
U.S. Food and Drug Administration. 2024. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma
Read next
What is the success rate of Rituxan (rituximab) in patients with blood cancers?
In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).
Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.
Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading
Does Truxima make you gain weight?
Weight gain has been reported in 11% of patients being treated with Truxima (rituximab) for non-Hodgkin’s lymphoma (NHL). Be sure to contact your doctor right away if you have a rapid or unexplained weight gain or fluid retention (edema), nausea, vomiting, diarrhea, or lack of energy when using Truxima, as you may need immediate medical care. Continue reading
What causes infusion reactions to rituximab?
Rituximab infusion reactions are caused primarily by cytokine release in the body. Cytokines are immune system proteins in the body that help to fight infections but can cause an inflammatory response. Infusion reactions may cause hives, itching, shortness of breath, chest pain or dizziness and are a very common side effect of treatment with rituximab (Rituxan). Continue reading
See also:
Aimovig
Learn about Aimovig (erenumab-aooe) a once-monthly, injectable medication that can be ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Epkinly
Epkinly is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ...
Nurtec ODT
Nurtec ODT (rimegepant) is used to treat acute migraines and prevent episodic migraines, by ...
Vyepti
Vyepti (eptinezumab-jjmr) is used for the preventive treatment of migraine. Includes Vyepti ...
Depakote
Depakote is used to treat various types of seizure disorders. Learn about side effects ...
Topamax
Topamax (topiramate) is used to prevent seizures in adults and children and to prevent migraine ...
Emgality
Emgality (galcanezumab-gnlm) is a CGRP antagonist for the preventive treatment of migraine and for ...
Inderal
Inderal (propranolol) is used to treat angina, high blood pressure and heart rhythm disorders ...
Related medical questions
- How does Monjuvi work?
- Is Adcetris a chemotherapy drug?
- What is the difference between Rituxan and Rituxan Hycela?
- How is Monjuvi given / administered?
- What is the success rate of Epkinly?
- How is Rituxan Hycela administered?
- What is the survival rate of Kymriah?
- What is the success rate of Monjuvi?
- What type of drug is Yescarta (axicabtagene ciloleucel)?
- How will I feel after a Rituxan infusion?
- How long does it take for Rituxan to work?
- How does the drug Rituxan work?
- Is Venclexta (venetoclax) chemotherapy?
- How do you prepare for a Rituxan infusion?
- How effective is Venclexta?
- Does ibrutinib cause hair loss?
- How long do you take Venclexta for?
- What are the names of the BTK inhibitors?
- Is Truxima a chemotherapy drug?
- How is Bendeka different to Treanda?
- How is Arzerra administered and how long to work?
- What is Arzerra used for and how does it work?
- Is Zydelig a chemotherapy drug?
- What is Zydelig used for and how does it work?
- Who makes Leukeran, and where is it made?
- How does Venclexta work?
- How long does it take for Jaypirca to work?
- How to apply for and use the Imbruvica copay card?
- What type of drug is Copiktra?
Drug information
- Breyanzi Information for Consumers
- Breyanzi prescribing info & package insert (for Health Professionals)
- Side Effects of Breyanzi (detailed)
Related support groups
- Breyanzi (1 questions, 3 members)
- Diffuse Large B-Cell Lymphoma (16 questions, 3 members)
- Chronic Lymphocytic Leukemia (CLL) (27 questions, 57 members)
- Follicular Lymphoma (15 questions, 15 members)
- Mantle Cell Lymphoma (9 questions, 9 members)
- B Cell Lymphoma (6 questions, 3 members)